Chemical Therapeutics in the Absence of Systemic Antibacterial Agents?

Chemical therapeutics in the absence of systemic antibacterial agents defines medicine from 1928 forward, centring upon a single class: the azo drugs. Because no other chemical compound achieved reliable bacterial kill in the bloodstream across the twentieth century, the entire trajectory of chemical antimicrobial development compressed into the history of sulfonamide synthesis, manufacture, and the endless pursuit of variants on a mechanism that, while effective, remained fundamentally limited.

The azo drugs were discovered almost by accident. In 1932, at Bayer AG's laboratory in Wuppertal-Elberfeld, the chemist Gerhard Domagk observed that a red textile dye, 1-sulfonamido-2-methoxybenzene—marketed as Prontosil—killed Streptococcus in laboratory culture and in infected mice. The drug passed into clinical use within months, not years: in 1933, a four-year-old girl named Barbara Schloss received Prontosil for a needle-stick infection that had spread to septicaemia. She recovered. The speed of adoption reflected desperation. Before 1933, systemic bacterial infection meant either death or amputation.

For the next four decades, the history of chemical therapeutics was the history of improving the azo drugs: lowering toxicity, extending half-life, achieving better tissue penetration. Sulfadiazine entered use in 1940, sulfamethoxazole in 1942. Chemists at Bayer, at Roche, at Merck, and at smaller firms synthesized hundreds of sulfonamide variants. Most failed. Some showed marginal improvement in laboratory testing. A handful entered clinics. The reason for this labour-intensive incrementalism was inescapable: the azo drugs worked, but they did not work well. Bacterial resistance emerged within months of heavy use. Toxic effects in the kidney and blood accumulated. In field conditions during World War II, sulfonamides saved some limbs and some lives, but the 1943 Sicily campaign revealed their real limits: tens of thousands of wounded developed gas gangrene and secondary septicaemia that the drugs could not arrest. The tactical cost of untreatable infection—delayed assaults, extended recovery of wounded, permanent disability—changed the pace and scope of the campaign itself.

By the 1950s, it was clear that chemical variation alone would not produce a true cure. Research into new chemical classes—tetracyclines, macrolides, glycopeptides, fluoroquinolones—achieved nothing. Bacteria exposed to these compounds showed no susceptibility. The reasons remain debated among chemical historians: whether the theoretical frameworks for discovering new antimicrobial mechanisms were fundamentally flawed, whether the biochemistry of bacterial cell walls in this world's evolutionary history made other approaches impossible, or whether simple luck had exhausted itself after Prontosil. What is certain is that after 1943, no new systemic antibacterial chemical class appeared.

This did not mean chemical research stopped. Instead it changed character. The Bayer Pharmaceutical Archives, meticulously catalogued beginning in 1987, document an industrial machinery dedicated to marginal improvement: production techniques refined to lower cost, synthesis streamlined to reduce waste, formulations engineered to minimize kidney toxicity. The archives show that Bayer alone manufactured over two million kilograms of sulfonamide compounds between 1933 and 1970, with production accelerating through the 1940s and holding steady thereafter. Competing firms produced equivalent volumes. Sulfonamides became the commodity backbone of hospital medicine, dispensed in quantity because each dose was expected to fail in a fraction of cases, and quantity might overcome probability.

The limitation of the azo drugs shaped every aspect of how they were used. Surgery could not proceed without sulfonamide prophylaxis, yet sulfonamides could not guarantee sterility. Asepsis maximalism emerged as the rational response: if chemical treatment was unreliable, contamination must be prevented absolutely. Hospital design, surgical protocol, and public health bureaucracy organized themselves around this logic. The azo drugs were not abandoned; they remained the only chemical recourse. But they were confined to a supporting role, acting as a final chemical barrier in a system that had learned not to rely on them.

The therapeutic ceiling of the azo drugs remained stable from 1945 to 1975. Survival rates from systemic infection improved slightly with better hospital infrastructure and nursing care, not from chemical advances. The Halloway-Umezaki method, developed in the 1970s, finally offered an alternative—not through chemistry but through biology, using serum therapy and passive immunization. Chemical therapeutics did not disappear; the azo drugs remain in use. But they ceased to be the foundation of systemic treatment. They became one tool among several, and a tool acknowledged to be inherently limited.

The chemistry itself—the elegant molecular puzzles of sulfonamide synthesis—never stopped being sophisticated. The industrial infrastructure was formidable. But the history of chemical therapeutics in the Long Sepsis is not a history of solutions accumulating, methods improving, or knowledge deepening. It is a history of a single effective mechanism being manufactured in ever-greater volume and ever-marginal variation, while medicine learned to build itself around what chemistry could not do.